Program
Simenafil Hydrochloride Tablets 2.5 mg
Also written as “Simenafil Hydrochloride Tablets 5 mg” and “Simenafil Hydrochloride Tablets 10 mg”.
Its studies are mostly in Alzheimer Disease, led by Vigonvita Life Sciences.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vigonvita Life Sciences | 11 open or running | phase 2since Oct 18, 2026 | Oct 18, 2026 | Sep 2028phase 2 · NCT07905352 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 18, 2026First study: phase 2 study in Alzheimer DiseaseFirst studyNCT07905352 · 200 planned · China
Ahead
- Sep 2028Primary completion: phase 2 study in Alzheimer DiseaseNCT07905352
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07905352Alzheimer Disease · China | 2 | Not yet recruiting | Sep 2028 | 200 |
How it is read
Names in the registry
- “Simenafil Hydrochloride Tablets 2.5 mg”, 1 entry
- “Simenafil Hydrochloride Tablets 5 mg”, 1 entry
- “Simenafil Hydrochloride Tablets 10 mg”, 1 entry
Conditions, from the studies’ own filings
- Alzheimer Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.